User login
Dr Harold J. Burstein, of the Dana-Farber Cancer Institute in Boston, Massachusetts, presents key abstracts on metastatic breast cancer (mBC) from the 2023 American Society of Clinical Oncology (ASCO) annual meeting.
Dr Burstein first highlights results from the SONIA study, which compared endocrine therapy followed by a CDK4/6 inhibitor in the second-line with the use of a CDK4/6 inhibitor in the first line. Although the CDK4/6 inhibitor in first-line improved progression-free survival, overall survival remained unchanged.
Dr Burstein next discusses results from the CANKADO trial, which randomized patients with mBC to report symptoms via a smartphone app. The app users reported fewer adverse events and better quality of life.
Dr Burstein reports on the potentially practice-changing results of the X-7/7 trial comparing a fixed dose of capecitabine (7/7) with the standard dose (14/7). Although both dosing schedules showed similar overall survival results, the fixed dose was better tolerated.
Finally, Dr Burstein turns to advances in the use of antibody-drug conjugates (ADCs), starting with an update from the TROPiCS-02 study comparing sacituzumab govitecan (SG) with standard chemotherapy. The 12.75-month follow-up showed an overall survival benefit when using SG in third- or fourth-line treatment.
He also highlights phase 2 trial results with another ADC, HER3-DXd (patritumab deruxtecan), which showed significant response rates across a broad range of HER3 expression levels.
--
Harold J. Burstein, MD, PhD, Professor, Department of Medicine, Harvard Medical School; Institute Physician, Dana-Farber Cancer Institute, Boston, Massachusetts
Harold J. Burstein, MD, PhD, has disclosed no relevant financial relationships.
Dr Harold J. Burstein, of the Dana-Farber Cancer Institute in Boston, Massachusetts, presents key abstracts on metastatic breast cancer (mBC) from the 2023 American Society of Clinical Oncology (ASCO) annual meeting.
Dr Burstein first highlights results from the SONIA study, which compared endocrine therapy followed by a CDK4/6 inhibitor in the second-line with the use of a CDK4/6 inhibitor in the first line. Although the CDK4/6 inhibitor in first-line improved progression-free survival, overall survival remained unchanged.
Dr Burstein next discusses results from the CANKADO trial, which randomized patients with mBC to report symptoms via a smartphone app. The app users reported fewer adverse events and better quality of life.
Dr Burstein reports on the potentially practice-changing results of the X-7/7 trial comparing a fixed dose of capecitabine (7/7) with the standard dose (14/7). Although both dosing schedules showed similar overall survival results, the fixed dose was better tolerated.
Finally, Dr Burstein turns to advances in the use of antibody-drug conjugates (ADCs), starting with an update from the TROPiCS-02 study comparing sacituzumab govitecan (SG) with standard chemotherapy. The 12.75-month follow-up showed an overall survival benefit when using SG in third- or fourth-line treatment.
He also highlights phase 2 trial results with another ADC, HER3-DXd (patritumab deruxtecan), which showed significant response rates across a broad range of HER3 expression levels.
--
Harold J. Burstein, MD, PhD, Professor, Department of Medicine, Harvard Medical School; Institute Physician, Dana-Farber Cancer Institute, Boston, Massachusetts
Harold J. Burstein, MD, PhD, has disclosed no relevant financial relationships.
Dr Harold J. Burstein, of the Dana-Farber Cancer Institute in Boston, Massachusetts, presents key abstracts on metastatic breast cancer (mBC) from the 2023 American Society of Clinical Oncology (ASCO) annual meeting.
Dr Burstein first highlights results from the SONIA study, which compared endocrine therapy followed by a CDK4/6 inhibitor in the second-line with the use of a CDK4/6 inhibitor in the first line. Although the CDK4/6 inhibitor in first-line improved progression-free survival, overall survival remained unchanged.
Dr Burstein next discusses results from the CANKADO trial, which randomized patients with mBC to report symptoms via a smartphone app. The app users reported fewer adverse events and better quality of life.
Dr Burstein reports on the potentially practice-changing results of the X-7/7 trial comparing a fixed dose of capecitabine (7/7) with the standard dose (14/7). Although both dosing schedules showed similar overall survival results, the fixed dose was better tolerated.
Finally, Dr Burstein turns to advances in the use of antibody-drug conjugates (ADCs), starting with an update from the TROPiCS-02 study comparing sacituzumab govitecan (SG) with standard chemotherapy. The 12.75-month follow-up showed an overall survival benefit when using SG in third- or fourth-line treatment.
He also highlights phase 2 trial results with another ADC, HER3-DXd (patritumab deruxtecan), which showed significant response rates across a broad range of HER3 expression levels.
--
Harold J. Burstein, MD, PhD, Professor, Department of Medicine, Harvard Medical School; Institute Physician, Dana-Farber Cancer Institute, Boston, Massachusetts
Harold J. Burstein, MD, PhD, has disclosed no relevant financial relationships.
